製品番号: HY-121240

Copy Link Print Information

Brecanavir

(別名: GW640385)

カスタマーレビュー

Based on 1 Customer Validation

Brecanavir (GW640385) is a novel, potent HIV protease inhibitor.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.79%
CAS 番号: 313682-08-5
分子式: C₃₃H₄₁N₃O₁₀S₂
分子量:703.82

保管条件:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Brecanavir 構造式

CAS 番号: 313682-08-5

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Brecanavir (GW640385) is a novel, potent HIV protease inhibitor.

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	EC₅₀	>90000 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human HeLa cells by HeLa-CD4 MAGI assay Antiviral activity against HIV1 HXB2 in human HeLa cells by HeLa-CD4 MAGI assay	[PMID: 17620375]
MDCK-II	IC₅₀	24.1 μM Compound: BRV	Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells	[PMID: 17664327]
MT2	IC₅₀	0.0002 μM Compound: BCV, brecanavir	Antiviral activity against HIV1 LAI in MT2 cells Antiviral activity against HIV1 LAI in MT2 cells	[PMID: 17635930]
MT2	IC₅₀	0.2 nM Compound: BCV, brecanavir	Antiviral activity against HIV1 LAI in MT2 cells Antiviral activity against HIV1 LAI in MT2 cells	[PMID: 17635930]
MT4	IC₅₀	0.22 nM Compound: 27	Antiviral activity against HIV1 I54V in MT4 cells Antiviral activity against HIV1 I54V in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	0.45 nM Compound: 27	Antiviral activity against nelfinavir resistant HIV1 14330 in MT4 cells Antiviral activity against nelfinavir resistant HIV1 14330 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	0.46 nM Compound: 27	Antiviral activity against indinavir resistant HIV1 30813 in MT4 cells Antiviral activity against indinavir resistant HIV1 30813 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	0.7 nM Compound: 27	Antiviral activity against HIV1 HXB2 in MT4 cells Antiviral activity against HIV1 HXB2 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	0.77 nM Compound: 27	Antiviral activity against multi PI resistant HIV1 EP14 in MT4 cells Antiviral activity against multi PI resistant HIV1 EP14 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	1.1 nM Compound: 27	Antiviral activity against HIV1 EP13 in MT4 cells Antiviral activity against HIV1 EP13 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	1.6 nM Compound: 27	Antiviral activity against HIV1 I50V in MT4 cells Antiviral activity against HIV1 I50V in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	1.7 nM Compound: 27	Antiviral activity against multi PI resistant HIV1 31246 in MT4 cells Antiviral activity against multi PI resistant HIV1 31246 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	4.8 nM Compound: 27	Antiviral activity against HIV D545701 in MT4 cells Antiviral activity against HIV D545701 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	5.4 nM Compound: 27	Antiviral activity against triple multi PI resistant HIV1 in MT4 cells Antiviral activity against triple multi PI resistant HIV1 in MT4 cells	[PMID: 16458505]
MT4	IC₅₀	8.2 nM Compound: 27	Antiviral activity against amprenavir resistant HIV1 468 in MT4 cells Antiviral activity against amprenavir resistant HIV1 468 in MT4 cells	[PMID: 16458505]
MT4	EC₅₀	0.44 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay	[PMID: 17620375]
MT4	EC₅₀	0.53 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect by MTS assay	[PMID: 17620375]
MT4	EC₅₀	0.7 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum by MTS assay	[PMID: 17620375]
MT4	EC₅₀	1.1 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 40% fetal bovine serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 40% fetal bovine serum by MTS assay	[PMID: 17620375]
MT4	EC₅₀	1.4 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 10% human serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 10% human serum by MTS assay	[PMID: 17620375]
MT4	EC₅₀	2.2 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 20% human serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 20% human serum by MTS assay	[PMID: 17620375]
MT4	EC₅₀	2.6 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 30% human serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 30% human serum by MTS assay	[PMID: 17620375]
MT4	EC₅₀	3.8 nM Compound: BCV, GW-640385	Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 40% human serum by MTS assay Antiviral activity against HIV1 HXB2 in human MT4 cells assessed as inhibition of viral-induced viral cytopathic effect in presence of 10% fetal bovine serum and 40% human serum by MTS assay	[PMID: 17620375]

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 313682-08-5
性状 Solid
分子量 703.82
分子式 C₃₃H₄₁N₃O₁₀S₂
Color White to off-white
SMILES

CC1=NC(COC2=CC=C(C[C@H](NC(O[C@H]3CO[C@@H]4[C@H]3CCO4)=O)[C@H](O)CN(S(=O)(C5=CC=C6C(OCO6)=C5)=O)CC(C)C)C=C2)=CS1
別名

GW640385
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

溶剤 & 溶解度

体外:

DMSO : 17.6 mg/mL (25.01 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.4208 mL

7.1041 mL

14.2082 mL

5 mM

0.2842 mL

1.4208 mL

2.8416 mL

10 mM

0.1421 mL

0.7104 mL

1.4208 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (274 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Ford SL, Reddy YS, Anderson MT, et al. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 2006;50(6):2201-2206. [Content Brief]

[2]. Reddy YS, Ford SL, Anderson MT, Murray SC, Ng-Cashin J, Johnson MA. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subj [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.4208 mL	7.1041 mL	14.2082 mL	35.5204 mL
	5 mM	0.2842 mL	1.4208 mL	2.8416 mL	7.1041 mL
	10 mM	0.1421 mL	0.7104 mL	1.4208 mL	3.5520 mL
	15 mM	0.0947 mL	0.4736 mL	0.9472 mL	2.3680 mL
	20 mM	0.0710 mL	0.3552 mL	0.7104 mL	1.7760 mL
	25 mM	0.0568 mL	0.2842 mL	0.5683 mL	1.4208 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Brecanavir

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Brecanavir 関連分類

HY-121240 関連分類